These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
338 related items for PubMed ID: 10319693
1. [Transfusion of blood and products derived from blood]. Wautier JL. Rev Prat; 1999 Feb 15; 49(4):409-13. PubMed ID: 10319693 [No Abstract] [Full Text] [Related]
2. [Indications for labile blood products]. Jeanne M, Rasonglès P. Rev Prat; 2001 Jun 30; 51(12):1318-27. PubMed ID: 11503505 [Abstract] [Full Text] [Related]
3. [For a reform of the legislation applied to plasma derivatives]. Pellet R. Rev Neurol (Paris); 2009 May 30; 165 Suppl 3():S88-94. PubMed ID: 19524100 [Abstract] [Full Text] [Related]
4. Haemovigilance and transfusion safety in France. Rouger P, Noizat-Pirenne F, Le Pennec PY. Vox Sang; 2000 May 30; 78 Suppl 2():287-9. PubMed ID: 10938971 [Abstract] [Full Text] [Related]
6. Manufacture of plasma-derived products in France and measures to prevent the risk of vCJD transmission: precautionary measures and efficacy of manufacturing processes in prion removal. Flan B, Arrabal S. Transfus Clin Biol; 2007 May 30; 14(1):51-62. PubMed ID: 17540602 [Abstract] [Full Text] [Related]
7. [Immunological aspects of blood transfusion preparations]. Matinlauri I. Duodecim; 2004 May 30; 120(7):867-75. PubMed ID: 15154308 [No Abstract] [Full Text] [Related]
8. Bibliography. Current world literature. Transfusion medicine. Curr Opin Hematol; 2001 Nov 30; 8(6):B140-51. PubMed ID: 11710320 [No Abstract] [Full Text] [Related]
9. [Blood and plasma transfusion in the treatment of acute blood loss]. Hiippala S. Duodecim; 2004 Nov 30; 120(7):893-901. PubMed ID: 15154311 [No Abstract] [Full Text] [Related]
10. [The current potentials for optimal whole-blood transfusion and component therapy with blood products--erythrocytes in obstetrics and gynecology--the indications, means and methods]. Nikolov A, Kovachev I, Gŭrcheva L, Dimitrov A. Akush Ginekol (Sofiia); 1998 Nov 30; 37(4):46-9. PubMed ID: 10360055 [No Abstract] [Full Text] [Related]
11. [Transfusion of blood and blood derivatives. Measurements of safety, circulatory, immunologic and infectious risks and accidents]. Rouger P, Hergon E. Rev Prat; 1997 Sep 01; 47(13):1499-504. PubMed ID: 9339033 [No Abstract] [Full Text] [Related]
12. [Risks of infection caused by blood and blood products with reference to the so-called AIDS scandal]. Kretschmer V. Infusionsther Transfusionsmed; 1993 Dec 01; 20(6):286-90. PubMed ID: 8142734 [No Abstract] [Full Text] [Related]
14. [Transfusion safety, experiences from the Le Havre Hospital Center]. Damais-Cepitelli A. Soins; 1998 Dec 01; (631):30-2. PubMed ID: 10095745 [No Abstract] [Full Text] [Related]
15. [Blood transfusion and blood product risks and alternatives (from the civil law viewpoint of the judge)]. Schlund GH. Geburtshilfe Frauenheilkd; 1994 Oct 01; 54(10):M133-6. PubMed ID: 8001747 [No Abstract] [Full Text] [Related]
16. [Infection control safety in blood transfusions]. Gargouri J, Brunot A, Souissi T. Tunis Med; 1993 Feb 01; 71(2):63-70. PubMed ID: 8322423 [No Abstract] [Full Text] [Related]
17. Limitations of component therapy for massive haemorrhage: is whole blood the whole solution? Hall S, Murphy MF. Anaesthesia; 2015 May 01; 70(5):511-4. PubMed ID: 25866037 [No Abstract] [Full Text] [Related]